NEONEURON, LLC

Biotech · Private

Induced pluripotent stem cell-derived dopaminergic neurons for intracerebral transplantation in Parkinson's disease, delivered via image-guided methodology

Grants
$700K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · IND-enabling studies for cell therapy in Parkinson's disease$465,228
Federal grantDepartment of Health and Human Services · Phase I · IND-enabling studies for cell therapy in Parkinson's disease$234,772
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2198SPHEREBIO, INC.——
2199Egaceutical Corp—$9K
2200ME THERAPEUTICS HOLDINGS INC.—$3K
2201NEONEURON, LLC——
2202PEPTIFORGE, INC——
2203BIOPROCESSING INNOVATIVE COMPANY INC——
2204ArCHitect Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 6
  • Method Of Treating Neurological Disorders With Stem Cell Therapyapplication
  • Device For Injecting Stem Cellsapplication
  • Method Of Treating Neurological Disorders With Stem Cell Therapyapplication
  • Device For Injecting Stem Cellsapplication
  • Method Of Treating Parkinson's Disease With Cell Therapyapplication
  • Device For Injecting Stem Cells Under Magnetic Resonance Imagingapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.